Hormone-dependent cancers rely on normal signalling pathways of the body in order to fuel their malignant potential. Fortunately, targeted therapies designed to deprive cancers of these growth signals have proven to be effective tools for treating patients with these types of cancers. New evidence published on August 5th by the New England Journal of Medicine now shows that combining androgen-deprivation therapy (ADT) and the chemotherapy drug docetaxel increases survival in patients with hormone-sensitive prostate cancer. The study found that patients receiving ADT and docetaxel together improved their survival by 13.6 months compared to patients receiving ADT alone.
Read more at the NEJM.
Skip to content
A Blog from the NewYork-Presbyterian/Weill Cornell Genitourinary (GU) Oncology Program
What's New in GU? 